- Home
- BCDA vs NLSP Comparison
BCDA vs NLSP Comparison
Compare BCDA & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- NLSP
- Stock Information
- Founded
- BCDA N/A
- NLSP 2015
- Country
- BCDA United States
- NLSP Switzerland
- Employees
- BCDA N/A
- NLSP N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- NLSP Health Care
- Exchange
- BCDA Nasdaq
- NLSP Nasdaq
- Market Cap
- BCDA 10.1M
- NLSP 12.4M
- IPO Year
- BCDA N/A
- NLSP 2021
- Fundamental
- Price
- BCDA $2.39
- NLSP $2.10
- Analyst Decision
- BCDA Strong Buy
- NLSP
- Analyst Count
- BCDA 1
- NLSP 0
- Target Price
- BCDA $25.00
- NLSP N/A
- AVG Volume (30 Days)
- BCDA 230.7K
- NLSP 275.3K
- Earning Date
- BCDA 08-12-2025
- NLSP 07-22-2025
- Dividend Yield
- BCDA N/A
- NLSP N/A
- EPS Growth
- BCDA N/A
- NLSP N/A
- EPS
- BCDA N/A
- NLSP N/A
- Revenue
- BCDA $3,000.00
- NLSP N/A
- Revenue This Year
- BCDA N/A
- NLSP N/A
- Revenue Next Year
- BCDA N/A
- NLSP N/A
- P/E Ratio
- BCDA N/A
- NLSP N/A
- Revenue Growth
- BCDA N/A
- NLSP N/A
- 52 Week Low
- BCDA $1.63
- NLSP $1.30
- 52 Week High
- BCDA $4.66
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- BCDA 58.67
- NLSP 46.61
- Support Level
- BCDA $1.98
- NLSP $2.20
- Resistance Level
- BCDA $2.45
- NLSP $3.08
- Average True Range (ATR)
- BCDA 0.17
- NLSP 0.25
- MACD
- BCDA 0.04
- NLSP -0.06
- Stochastic Oscillator
- BCDA 88.00
- NLSP 8.40
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.